Aspen Neuroscience Scores $70M Series A Back to HomeSAN DIEGO, CA, Aspen Neuroscience announced the close of its Series A funding round of $70 million led by OrbiMed.

Aspen Neuroscience, a private biotechnology company developing the first autologous neuron replacement therapy to treat Parkinson disease, today announced the close of its Series A funding round of $70 million.

"Our mission at Aspen Neuroscience is to develop a restorative, disease modifying autologous neuron therapy for people suffering from Parkinson disease," said Dr. Howard Federoff, Chief Executive Officer of Aspen Neuroscience.

Aspen's second product, ANPD002, combines gene correction and autologous neuron therapy for the treatment of genetic forms of Parkinson disease.

Aspen's therapies are based upon the scientific work of world-renowned stem cell scientist, Dr. Jeanne Loring, who has developed a novel method for autologous neuron replacement. | To read full story, visit https://startuparound.com/read/1585778408.1062064/Aspen-Neuroscience-Scores-$70M-Series-A?ref=audio_experience